Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.

Literature DB >> 18509356

Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.

H Deng, N Tang, A E Stief, N Mehta, E Baig, R Head, G Sleep, X-Z Yang, C McKerlie, S Trudel, A K Stewart, J A McCart.

Abstract

Entities: Disease Species

Mesh：

Year: 2008 PMID： 18509356 DOI： 10.1038/leu.2008.120

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

1. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.

Authors: Kah-Whye Peng; Ahmet Dogan; Julie Vrana; Chunsheng Liu; Hooi T Ong; Shaji Kumar; Angela Dispenzieri; Allan B Dietz; Stephen J Russell
Journal: Am J Hematol Date: 2009-07 Impact factor: 10.047

2. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Authors: XueQing Lun; Jennifer Chan; Hongyuan Zhou; Beichen Sun; John J P Kelly; Owen Owen Stechishin; John C Bell; Kelley Parato; Kang Hu; Dominique Vaillant; Jiahu Wang; Ta-Chiang Liu; Caroline Breitbach; David Kirn; Donna L Senger; Peter A Forsyth
Journal: Mol Ther Date: 2010-08-31 Impact factor: 11.454

8. Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.

Authors: Katherine M Dunlap; Mee Y Bartee; Eric Bartee
Journal: Oncolytic Virother Date: 2015-01-13

Review 9. Molecular imaging of oncolytic viral therapy.

Authors: Dana Haddad; Yuman Fong
Journal: Mol Ther Oncolytics Date: 2015-02-04 Impact factor: 7.200

10. Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.

Authors: Yingzhe Jiang; Kotaro Saga; Yasuhide Miyamoto; Yasufumi Kaneda
Journal: Oncotarget Date: 2016-06-14

Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.

1. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.

2. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

3. Oncolytic virotherapy for multiple myeloma: past, present, and future.

4. Oncolytic virotherapy for hematological malignancies.

5. Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.

Review 6. Potential of oncolytic viruses in the treatment of multiple myeloma.

Review 7. The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications.

8. Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma.

Review 9. Molecular imaging of oncolytic viral therapy.

10. Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene.